Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.400
-0.020 (-1.41%)
At close: Dec 5, 2025, 4:00 PM EST
1.380
-0.020 (-1.43%)
After-hours: Dec 5, 2025, 7:30 PM EST
Lexicon Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 70.86 | 31.08 | 1.2 | 0.14 | 0.3 | 24 | Upgrade
|
| Revenue Growth (YoY) | 1255.21% | 2481.48% | 766.19% | -53.36% | -98.76% | -92.55% | Upgrade
|
| Cost of Revenue | 75.81 | 84 | 58.97 | 52.52 | 55.05 | 153.05 | Upgrade
|
| Gross Profit | -4.95 | -52.92 | -57.77 | -52.38 | -54.75 | -129.06 | Upgrade
|
| Selling, General & Admin | 49.62 | 131.9 | 112.54 | 48.08 | 32.34 | 44.23 | Upgrade
|
| Operating Expenses | 49.62 | 131.9 | 112.54 | 48.08 | 32.34 | 44.23 | Upgrade
|
| Operating Income | -54.57 | -184.82 | -170.31 | -100.46 | -87.09 | -173.29 | Upgrade
|
| Interest Expense | -10.17 | -15.58 | -13.1 | -2.78 | -0.8 | -14.54 | Upgrade
|
| Interest & Investment Income | 8.46 | 12.29 | 7.73 | 1.6 | 0.13 | 2.77 | Upgrade
|
| EBT Excluding Unusual Items | -56.28 | -188.1 | -175.68 | -101.64 | -87.76 | -185.06 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -5.5 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 132.59 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -1.6 | Upgrade
|
| Other Unusual Items | -12.3 | -12.3 | -1.44 | -0.3 | - | 1 | Upgrade
|
| Pretax Income | -68.58 | -200.4 | -177.12 | -101.94 | -87.76 | -58.57 | Upgrade
|
| Net Income | -68.58 | -200.4 | -177.12 | -101.94 | -87.76 | -58.57 | Upgrade
|
| Net Income to Common | -68.58 | -200.4 | -177.12 | -101.94 | -87.76 | -58.57 | Upgrade
|
| Shares Outstanding (Basic) | 363 | 320 | 221 | 166 | 146 | 111 | Upgrade
|
| Shares Outstanding (Diluted) | 363 | 320 | 221 | 166 | 146 | 111 | Upgrade
|
| Shares Change (YoY) | 24.67% | 44.73% | 33.42% | 13.79% | 31.41% | -5.06% | Upgrade
|
| EPS (Basic) | -0.19 | -0.63 | -0.80 | -0.62 | -0.60 | -0.53 | Upgrade
|
| EPS (Diluted) | -0.19 | -0.63 | -0.80 | -0.62 | -0.60 | -0.53 | Upgrade
|
| Free Cash Flow | -72.58 | -179.81 | -162.37 | -90.18 | -88.24 | -143.06 | Upgrade
|
| Free Cash Flow Per Share | -0.20 | -0.56 | -0.73 | -0.54 | -0.61 | -1.29 | Upgrade
|
| Gross Margin | -6.98% | -170.25% | - | - | - | - | Upgrade
|
| Operating Margin | -77.00% | -594.63% | -14145.35% | -72273.38% | -29224.83% | -722.17% | Upgrade
|
| Profit Margin | -96.77% | -644.78% | -14710.88% | -73341.01% | -29448.99% | -244.11% | Upgrade
|
| Free Cash Flow Margin | -102.43% | -578.52% | -13485.63% | -64875.54% | -29610.07% | -596.19% | Upgrade
|
| EBITDA | -53.94 | -184.28 | -169.76 | -100.03 | -86.8 | -170.35 | Upgrade
|
| EBITDA Margin | -76.12% | - | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.63 | 0.53 | 0.55 | 0.43 | 0.29 | 2.93 | Upgrade
|
| EBIT | -54.57 | -184.82 | -170.31 | -100.46 | -87.09 | -173.29 | Upgrade
|
| EBIT Margin | -77.00% | - | - | - | - | - | Upgrade
|
| Revenue as Reported | 70.86 | 31.08 | 1.2 | 0.14 | 0.3 | 24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.